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Background:  Inflammatory cell recruitment and intimal neovascularization contribute to atherosclerotic plaque vulnerability. Inhibition of 
cell migration may thus be a useful approach to prevent plaque development and destabilization. Resveratrol, the anti-inflammatory red wine 
polyphenol, was implicated in cardiovascular protection. In this study, we investigated the effects of resveratrol on endothelial and monocytic cell 
migration.
Methods:  Chemotaxis of THP-1 monocytic cells towards monocyte chemotactic protein (MCP)-1 was determined using Boyden chamber. MCP-1 
receptor (CCR2) expression and ERK phosphorylation was determined by Western blotting. Human umbilical vein endothelial cell (EC) migration was 
assessed in a modified barrier assay.
Results:  Resveratrol significantly inhibited monocytic cell chemotaxis towards MCP-1 already at 1 μmol/L. At resveratrol concentration of 10 
μmol/L, chemotaxis was reduced nearly to negative control (unstimulated with MCP-1) levels. This effect was independent of NF-kappaB signalling. 
In resveratrol-treated monocytic cells slight reduction in the protein expression CCR2 was observed. However, MCP-1-induced ERK phosphorylation 
downstream of CCR2 receptor was dose-dependently inhibited by resveratrol, as observed by Western blot analysis.
In resveratrol-treated endothelial cells, a progressive shape elongation was observed, evident after 6h of treatment. Moreover, resveratrol (1-20 
μmol/L) dose-dependently inhibited spontaneous EC migration. These effects of resveratrol were independent of nuclear factor(NF)-kappaB, but were 
abrogated in presence of RhoA kinase inhibitors, indicating a novel mechanism by which resveratrol affects EC cytoskeleton and functions.
Conclusions:  Resveratrol dose-dependently inhibited endothelial cell migration and MCP-1-induced monocytic cell chemotaxis. This activity may 
contribute to the cardioprotective effects of resveratrol by inhibition of intimal neovascularization and monocyte recruitment into the artery wall.
